Drug intelligence / Profile preview

Pylosan

Development stage: Unknown
Lead developer: Laves-Arzneimittel
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

Pylosan is a dietary supplement, specifically categorized as a food for special medical purposes (FSMP), developed by Laves-Arzneimittel for the dietary management of *Helicobacter pylori*-associated gastritis and the support of intestinal and immune health. The product contains a combination of inactivated *Lactobacillus reuteri* DSM 17648 (commercially known as Pylopass), zinc, and vitamin B12 (cyanocobalamin). Its primary mechanism of action involves the specific physical binding of the inactivated *L. reuteri* cells to *H. pylori* bacteria in the stomach. This interaction forms co-aggregates that are naturally eliminated through the digestive tract, thereby reducing the gastric bacterial load without disrupting the normal gut microbiota. The inclusion of zinc and vitamin B12 is intended to support the regeneration of the gastric mucosa and bolster the immune system's response to infection.

Brand names: Pylosan
Other names: Pylosan Laves

Beyond the preview

Go deeper on Pylosan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pylosan.

Explore the full profile